Avantor plans to acquire VWR for approximately $6.4 billion cash, in a deal the companies said today would create a combined global provider of consumables-focused solutions and services to life sciences and advanced technologies businesses, as well as education, government, and research institutions.
The deal is designed to enable the combined company to serve customers from research through production by joining Avantor’s strengths in cGMP manufacturing processes and significant exposure to emerging markets with VWR’s focus on providing product and service solutions to laboratory and production customers in the Americas and Europe.
“Given the changing dynamics in the highly fragmented and diverse life sciences sector, we believe that combining Avantor’s advanced materials and solutions with VWR’s unparalleled distribution capabilities and breadth of offerings represents a compelling value proposition,” said VWR president and CEO Manuel Brocke-Benz.
The boards of both companies have approved the deal, which is expected to close in the third quarter, subject to VWR shareholder approval and other conditions that include expiration of a “go-shop” period, the expiration or termination of the applicable waiting period under Hart–Scott–Rodino Antitrust Improvements Act, and European Commission approval.
Full Content: Gen News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas